Recent Developments in the Nanostructured Materials Functionalized with Ruthenium Complexes for Targeted Drug Delivery to Tumors

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2017 Apr 25

PMID 28435255

Citations 14

Authors

Prakash Thangavel

Buddolla Viswanath

Sanghyo Kim

Affiliations

Soon will be listed here.

Abstract

In recent years, the field of metal-based drugs has been dominated by other existing precious metal drugs, and many researchers have focused their attention on the synthesis of various ruthenium (Ru) complexes due to their potential medical and pharmaceutical applications. The beneficial properties of Ru, which make it a highly promising therapeutic agent, include its variable oxidation states, low toxicity, high selectivity for diseased cells, ligand exchange properties, and the ability to mimic iron binding to biomolecules. In addition, Ru complexes have favorable adsorption properties, along with excellent photochemical and photophysical properties, which make them promising tools for photodynamic therapy. At present, nanostructured materials functionalized with Ru complexes have become an efficient way to administer Ru-based anticancer drugs for cancer treatment. In this review, the recent developments in the nanostructured materials functionalized with Ru complexes for targeted drug delivery to tumors are discussed. In addition, information on "traditional" (ie, non-nanostructured) Ru-based cancer therapies is included in a precise manner.

Citing Articles

Advanced applications of DNA nanostructures dominated by DNA origami in antitumor drug delivery.

Zhang Y, Tian X, Wang Z, Wang H, Liu F, Long Q Front Mol Biosci. 2023; 10:1239952.

PMID: 37609372 PMC: 10440542. DOI: 10.3389/fmolb.2023.1239952.

Ecofriendly ruthenium-containing nanomaterials: synthesis, characterization, electrochemistry, bioactivity and catalysis.

Gupta P, Mishra L Nanoscale Adv. 2022; 2(5):1774-1791.

PMID: 36132502 PMC: 9418862. DOI: 10.1039/d0na00051e.

Polymeric Nanosystems Applied for Metal-Based Drugs and Photosensitizers Delivery: The State of the Art and Recent Advancements.

Ferreira Dantas K, Rosario J, Pereira Silva-Caldeira P Pharmaceutics. 2022; 14(7).

PMID: 35890401 PMC: 9320085. DOI: 10.3390/pharmaceutics14071506.

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Ferraro M, Piccolo M, Misso G, Santamaria R, Irace C Pharmaceutics. 2022; 14(5).

PMID: 35631543 PMC: 9147010. DOI: 10.3390/pharmaceutics14050954.

Synthesis and characterization of a novel ruthenium(ii) trisbipyridine complex magnetic nanocomposite for the selective oxidation of phenols.

Fei Z, Chen F, Zhong M, Qiu J, Li W, Sadeghzadeh S RSC Adv. 2022; 9(48):28078-28088.

PMID: 35530489 PMC: 9070753. DOI: 10.1039/c9ra05079e.

References

Huang Y, Huang W, Chan L, Zhou B, Chen T . A multifunctional DNA origami as carrier of metal complexes to achieve enhanced tumoral delivery and nullified systemic toxicity. Biomaterials. 2016; 103:183-196. DOI: 10.1016/j.biomaterials.2016.06.053. View

Kubanik M, Kandioller W, Kim K, Anderson R, Klapproth E, Jakupec M . Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems. Dalton Trans. 2016; 45(33):13091-103. DOI: 10.1039/c6dt01110a. View

Levina A, Mitra A, Lay P . Recent developments in ruthenium anticancer drugs. Metallomics. 2011; 1(6):458-70. DOI: 10.1039/b904071d. View

Yang J, Cao Q, Hu W, Ye R, He L, Ji L . Theranostic TEMPO-functionalized Ru(ii) complexes as photosensitizers and oxidative stress indicators. Dalton Trans. 2016; 46(2):445-454. DOI: 10.1039/c6dt04028d. View

Grozav A, Miclaus V, Vostinaru O, Ghibu S, Berce C, Rotar I . Acute toxicity evaluation of a thiazolo arene ruthenium (II) complex in rats. Regul Toxicol Pharmacol. 2016; 80:233-40. DOI: 10.1016/j.yrtph.2016.06.018. View

Mehta J, Gajera S, Patel M . Biological applications of pyrazoline-based half-sandwich ruthenium(III) coordination compounds. J Biomol Struct Dyn. 2016; 35(7):1599-1607. DOI: 10.1080/07391102.2016.1189360. View

Chen L, Fu C, Deng Y, Wu W, Fu A . A pH-Sensitive Nanocarrier for Tumor Targeting : Delivery of Ruthenium Complex for Tumor Theranostic by pH-Sensitive Nanocapsule. Pharm Res. 2016; 33(12):2989-2998. DOI: 10.1007/s11095-016-2021-2. View

Kurzwernhart A, Kandioller W, Bachler S, Bartel C, Martic S, Buczkowska M . Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands. J Med Chem. 2012; 55(23):10512-22. DOI: 10.1021/jm301376a. View

Mari C, Pierroz V, Ferrari S, Gasser G . Combination of Ru(ii) complexes and light: new frontiers in cancer therapy. Chem Sci. 2018; 6(5):2660-2686. PMC: 5639435. DOI: 10.1039/c4sc03759f. View

10.

Chow M, Babak M, Wong D, Pastorin G, Gaiddon C, Ang W . Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes. Mol Pharm. 2016; 13(7):2543-54. DOI: 10.1021/acs.molpharmaceut.6b00348. View

11.

Caruso F, Pettinari R, Rossi M, Monti E, Gariboldi M, Marchetti F . The in vitro antitumor activity of arene-ruthenium(II) curcuminoid complexes improves when decreasing curcumin polarity. J Inorg Biochem. 2016; 162:44-51. DOI: 10.1016/j.jinorgbio.2016.06.002. View

12.

Jayanthi E, Kalaiselvi S, Padma V, Bhuvanesh N, Dharmaraj N . Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release. Dalton Trans. 2015; 45(4):1693-707. DOI: 10.1039/c5dt03849a. View

13.

Rojas S, Carmona F, Barea E, Maldonado C . Inorganic mesoporous silicas as vehicles of two novel anthracene-based ruthenium metalloarenes. J Inorg Biochem. 2016; 166:87-93. DOI: 10.1016/j.jinorgbio.2016.11.004. View

14.

Sava G, Zorzet S, Turrin C, Vita F, Soranzo M, Zabucchi G . Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res. 2003; 9(5):1898-905. View

15.

Carneiro Z, Biazzotto J, Alexiou A, Nikolaou S . Nitric oxide photorelease from a trinuclear ruthenium nitrosyl complex and its in vitro cytotoxicity against melanoma cells. J Inorg Biochem. 2014; 134:36-8. DOI: 10.1016/j.jinorgbio.2014.01.012. View

16.

Jovanovic K, Gligorijevic N, Gaur R, Mishra L, Radulovic S . Anticancer activity of two ruthenium(II)-DMSO-chalcone complexes: Comparison of cytotoxic, pro-apoptotic and antimetastatic potential. J BUON. 2016; 21(2):482-90. View

17.

Domotor O, de Almeida R, Corte-Real L, Matos C, Marques F, Matos A . Studies on the mechanism of action of antitumor bis(aminophenolate) ruthenium(III) complexes. J Inorg Biochem. 2016; 168:27-37. DOI: 10.1016/j.jinorgbio.2016.12.008. View

18.

Sava G, Frausin F, Cocchietto M, Vita F, Podda E, Spessotto P . Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. Eur J Cancer. 2004; 40(9):1383-96. DOI: 10.1016/j.ejca.2004.01.034. View

19.

Dalton S, Glazier S, Leung B, Win S, Megatulski C, Burgmayer S . DNA binding by Ru(II)-bis(bipyridine)-pteridinyl complexes. J Biol Inorg Chem. 2008; 13(7):1133-48. DOI: 10.1007/s00775-008-0399-y. View

20.

Lima A, Pereira F, Almeida M, Mello F, Pires W, Pinto T . Cytoxicity and apoptotic mechanism of ruthenium(II) amino acid complexes in sarcoma-180 tumor cells. PLoS One. 2014; 9(10):e105865. PMC: 4201456. DOI: 10.1371/journal.pone.0105865. View